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The ob jec t ive  of t h i s  experiment is t o  measure t he  
e x c i t a t i o n  funct ions  of proton-induced nuclear  r eac t ions  
f o r  fou r  radionucl ides  of va lue  i n  nuclear  medicine. 
Cross s ec t ions  of Ru-97 and Tc-96 formed i n  rhodium 
t a r g e t s  a s  wel l  a s  Cd-109 and Sn-113 formed i n  indium 
t a r g e t s  w i l l  be determined f o r  proton energies  from 40 
t o  200 MeV. These da t a  w i l l  provide a b a s i s  f o r  se- 
l e c t i n g  optimal i r r a d i a t i o n  condi t ions  and ca l cu l a t i ng  
th ick- targe t  y i e l d s  f o r  la rge-sca le  prepara t ions  a t  t h e  
Brookhaven Linac Iso tope  Producer (BLIP). 
Ru-97, Tc-96, Cd-109, and Sn-113 a r e  of  consider- 
a b l e  i n t e r e s t  f o r  biomedical and o t h e r  app l i ca t ions .  
Ru-97 is  a p o t e n t i a l  radionuclide f o r  nuclear  medicine 
app l i ca t ions  t o  nuclear  oncology because of i ts  des i r -  
ab l e  phys ica l  c h a r a c t e r i s t i c s  ( t+ - 2.9 d, 86% 216 keV 
gammas) and t h e  high chemical r e a c t i v i t y  of ruthenium. 
I n  addi t ion ,  a number of ruthenium compounds have shown 
promise a s  u se fu l  agents  i n  cancer chemotherapy.') The 
convenient h a l f - l i f e  of Tc-96 (4.3 d) makes it a va luable  
t r a c e r  f o r  developing new radiopharmaceuticals  of i t s  
short- l ived i so tope ,  Tc-99m (6.02 h ) ,  which has  found 
extensive app l i ca t ion  i n  nuclear  medicine. Cd-109 
( t k  = 453 d) is i n  equil ibrium wi th  i t s  daughter, Ag-109m 
( t g  = 40 s ) ,  which emits a s i n g l e  88-keV gamma ray  
(3.92% abundant). It is  usefu l  a s  a X-ray f luorescence 
o r  radiography source. The nuclear  p rope r t i e s  of t h e  
Cd-1091Ag-109m p a i r  a l s o  s a t i s f y  the  requirements f o r  a 
generator  system which would provide a continuous source 
of  u l t rashor t - l ived  medical nucl ide  for repeated dynamic 
~ t u d i e s . ~ )  Sn-113 ( t 4  = 114.9 d)  is  t h e  parent  nucl ide  
f o r  t h e  important In-113m generator  system. The In-113m 
genera tor  has  been shown t o  be of value i n  many nuclear  
imaging app l i ca t ions .  The des i r ab l e  c h a r a c t e r i s t i c s  
of In-113m inc lude  a sho r t -ha l f - l i f e  of 1.658 h,  a mono- 
energet ic  gamma emission of 392 keV (65% abundant), and 
no be t a  emissions t o  con t r ibu t e  t o  the  r a d i a t i o n  dosage. 
The Brookhaven Linac Iso tope  Producer (BLIP) 5, ' 6, 
has  been i n  a c t i v e  use  f o r  t h e  pas t  few years  f o r  pre- 
paring l a r g e  q u a n t i t i e s  of rad ionucl ides  of medical 
i n t e r e s t .  It u t i l i z e s  t h e  excess beam capaci ty  of a 
200~MeV proton Linac t h a t  i n j e c t s  protons i n t o  t he  
Al terna te  Gradient Synchrotron, a 33-GeV acce l e ra to r  
used i n  high-energy physics research .  The Linac can 
generate up t o  10  pu l se s  of 200-MeV per second, pro- 
v id ing  beam c u r r e n t s  of 70 t o  100 microamperes f o r  
rad ionucl ide  production. Prepara t ions  of c l i n i c a l l y  
u se fu l  q u a n t i t i e s  of Ru-97 and Tc-96 from a rhodium 
t a r g e t ,  and Cd-109 and Sn-113 from an indium t a r g e t  a t  
t he  BLIP have been demonstrated t o  be  f e a s i b l e .  The 
p r inc ipa l  nuclear  r eac t ions  involved a r e  Rh-103 (p, 2p5n) 
Ru-97, Rh-103 (p, 3p5n)-Tc-96, In-115 (p, 2p5e) Cd-109, and 
In-115(p,3n)Sn-113. The experimental determination of 
th in- ta rge t  c r o s s  s ec t ions  of t he se  r eac t ions  w i l l  
al low t h e  s e l e c t i o n  of optimal bombardment condi t ions  
and an es t imat ion  of s p e c i f i c  rad ionucl ide  y i e l d s  i n  
t h i c k  t a r g e t s .  
A l l  c r o s s  s ec t ion  determinations w i l l  b e  made by 
a c t i v a t i o n  of  t a r g e t s  followed by measurement of the  
a c t i v i t y  of  t h e  des i red  product wi th  Ge(Li) de t ec to r  
gamma-ray counting. No chemical separa t ions  a r e  
necessary. I r r a d i a t i o n s  w i l l  be c a r r i e d  out  i n  t he  
ex t e rna l  beam of t h e  Indiana Univers i ty  200-MeV cyclo- 
t ron .  The proton f l u x  w i l l  be  monitored by means of a 
Faraday cup. High-purity metal  f o i l s  of rhodium and 
indium a r e  used a s  t a r g e t s .  Exci ta t ion  funct ions  f o r  
a l l  r eac t ions  w i l l  b e  meaqured i n  t h e  proton energy 
range of 40 t o  200 MeV (12 t a r g e t s  each, a t  'L 15 MeV 
i n t e r v a l s ) .  The i r r a d i a t e d  t a r g e t s  w i l l  b e  shipped t o  
Brookhaven and the  r ad ioac t ive  products  i n  t h e  individ-  
ua l  rhodium and indium f o i l s  measured by gamma-ray 
spectroscopy using a c a l i b r a t e d  Ge(Li) de t ec to r .  
To d a t e  i r r a d i a t i o n s  a t  60, 80, 96, 115, 149, 159, 
174 and 200 MeV have been made. Analysis  of t h e  y-ray 
spec t r a  taken over a period of a few months i s  requi red  
before  experimental va lues  can be quoted. 
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